Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | LPO | P22079 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4980288 | 1.00 | CCR2 (0.33) | CCR2KCNH2LPOKDM4EMEN1 | |
| SCHEMBL18270144 | 0.79 | SLC6A4 (0.42) | CCR2KCNH2LPOKDM4EMEN1 | |
| SCHEMBL20690952 | 0.77 | SLC6A4 (0.38) | CCR2KCNH2LPOKDM4EALDH1A1 | |
| SCHEMBL22212218 | 0.77 | KDM4E (0.33) | CCR2KCNH2LPOKDM4EALDH1A1 | |
| SCHEMBL14950644 | 0.77 | OPRM1 (0.33) | CCR2KCNH2LPOKDM4EALDH1A1 | |
| SCHEMBL20690972 | 0.77 | CCR2 (0.35) | CCR2KCNH2LPOKDM4EALDH1A1 | |
| SCHEMBL20690974 | 0.76 | LPO (0.30) | LPO | |
| SCHEMBL12178944 | 0.75 | — | — | |
| SCHEMBL18270124 | 0.73 | OPRM1 (0.37) | CCR2KCNH2ALDH1A1 | |
| SCHEMBL16992528 | 0.72 | DRD2 (0.40) | CCR2KCNH2LPOMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080021038-A1 | Novel Piperidine/8-Azabicyclo [3.2.1.] Octan Derivatives As Modulators Of Chemokine Receptor Ccr5 | TUCKER HOWARD | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021038-A1 | Novel Piperidine/8-Azabicyclo [3.2.1.] Octan Derivatives As Modulators Of Chemokine Receptor Ccr5 | CCR5, CXCR1, CCR2 | CCR2 3/4885KCNH2 1730/4885LPO 4410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.